Table 1 Clinical characteristics, pattern of care and outcome of HIV-seronegative patients (n = 81). MMC = mitomycin-C, RT = radiotherapy, OS = overall survival, CSS = cancer-specific survival, m = months.
Variable | HIV-seronegative patients |
|---|---|
gender | m:f = 20:61 (24.7%) |
age | 61.6 +/- 12.7 y |
WHO performance status I° | 14.8 % |
T1/T2/T3/T4 | 14.8 %/43.2 %/30.9 %/11.1 % |
N0/N1/N2/N3 | 60.5 %/17.3 %/11.1 %/8.6 % |
G 1/G 2/G 3 | 8.6 %/53.1 %/27.2 % |
sphincter invasion | 25 (30.9 %) |
histology (basaloid) | 25 (30.9 %) |
radical surgery | 5 (6 %) |
chemotherapy | 58 (71.6 %) |
MMC | 52 (64.2 %) |
RT-dose | 57.2 +/- 5 Gy |
RT-duration | 53.6 +/- 17.3 d |
brachytherapy | 34 (41.9 %) |
follow-up (median/mean) | 45 m/51 +/- 34 m |
OS at 10 years | 48 % |
CSS at 10 years | 75.1 % |
acute side effects (3°) | 25 (30.9 %) |
skin | 14 (17.3 %) |
diarrhea | 5 (6.2 %) |
hematological (% of MMC patients) | 6 (11.5 %) |
infection | 3 (3.7 %) |
other | 1 (1.2 %) |
chronic side effects (n = 54) | 13 (24 %) |
ulcera | 1 (1.9 %) |
proctitis | 6 (11.1 %) |
sphincter pressure impairment | 8 (14.8 %) |